Novo Nordisk A/S

NOVO B

DK0062498333

Pharmaceuticals

Market Closed - Nasdaq Copenhagen Other stock markets 11:20:00 2025-12-05 EST			5-day change	1st Jan Change
309.60 ^DKK	+1.24%		-2.33%	-50.40%

12-05	Sector Update: Health Care Stocks Lower Late Afternoon	MT
12-05	Sector Update: Health Care Stocks Decline Friday Afternoon	MT

NOVO NORDISK : Goldman Sachs gives a Buy rating

Published on 08/04/2025 at 04:28 am EDT

MarketScreener with dpa-AFX Analyser

Novo Nordisk A/S

+1.24%

Goldman Sachs is positive on the stock with a Buy rating. The target price is lowered from DKK 745 to DKK 400.

Latest news about Novo Nordisk A/S

12-05	Sector Update: Health Care Stocks Lower Late Afternoon	MT
12-05	Sector Update: Health Care Stocks Decline Friday Afternoon	MT
12-05	European Equities Close Mixed in Friday Trading; EU GDP Grows 0.4% in Q3	MT
12-05	European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading	MT
12-05	Sector Update: Health Care Stocks Rise Pre-Bell Friday	MT
12-05	Berenberg Says Novo Nordisk Deserves Higher Valuation, Shares Rise - BN	FW
12-05	Novo Nordisk Loses India Case to Halt Dr. Reddy's Production of Generic Semaglutide	MT
12-05	India's Healthify eyes more weight-loss drugmaker tie-ups after Novo Nordisk pact	RE
12-05	NOVO NORDISK : Berenberg gives a Buy rating	ZD
12-04	Novo Nordisk Presents New Topline Results from Their Evoke and Evoke+ Phase 3 Trials of Semaglutide	CI
12-04	Indian Court Allows Dr. Reddy's to Produce Generic Versions of Novo Nordisk's Blockbuster Drugs -- 2nd Update	DJ
12-04	Indian Court Allows Dr. Reddy's to Produce Generic Versions of Novo Nordisk's Blockbuster Drugs -- Update	DJ
12-04	Novo Nordisk Loses India Case to Halt Dr. Reddy's Production of Generic Semaglutide	MT
12-04	Novo Nordisk Eyes Launching Ozempic in India This Month	MT
12-04	Novo Nordisk gears up for Ozempic launch in India, sources say	RE
12-04	Indian Court Allows Dr. Reddy's to Produce Generic Versions of Novo Nordisk's Blockbuster Drugs	DJ
12-04	NOVO NORDISK : UBS reaffirms its Neutral rating	ZD
12-04	Bråse's Fund Sells All Shares in Novo Nordisk	FW
12-04	Germany's cartel office says it approved acquisition of Akero Therapeutics by Novo Nordisk	RE
12-04	Germany's cartel office says it approved acquisition of Akero Therapeutics by Novo Nordisk	RE
12-04	UBS Lowers Price Target for Novo Nordisk to 295 Danish Kroner, Reiterates Neutral Rating	FW
12-04	Novo Nordisk Open to Further Development of Ozempic for Alzheimer's Despite Failed Trials	FW
12-04	Denmark raises growth outlook despite Novo Nordisk woes	RE
12-04	Denmark Investigates Whether Novo Nordisk Should Pay Wegovy-Related Eye Disease Compensation - DR	FW
12-04	Novo Nordisk to Launch Ozempic in India in Coming Weeks - Reuters	FW

Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows: - diabetes and obesity treatment products (93.6%); - rare disease treatment products (6.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc. Net sales are distributed geographically as follows: Europe/Middle East/Africa (20.8%), the United States (57.6%), North America (3.7%), China (6.4%) and other (11.5%).

Employees

78,554

Sector

Pharmaceuticals

Calendar

02-04 - Q4 2025 Earnings Release

More about the company